Saudi Arabia Generic Drug Market Overview

Market Size in 2024: USD 3.8 Billion

Market Size in 2033: USD 8.0 Billion

Market Growth Rate 2025-2033: 7.9%

According to IMARC Group's latest research publication, "Saudi Arabia Generic Drug Market: Industry Trends, Share, Size, Growth, Opportunity and Forecast 2025-2033", The Saudi Arabia generic drug market size was valued at USD 3.8 Billion in 2024. Looking forward, IMARC Group estimates the market to reach USD 8.0 Billion by 2033, exhibiting a CAGR of 7.9% during 2025-2033.

How AI is Reshaping the Future of Saudi Arabia Generic Drug Market

• Accelerating Drug Development: AI-powered molecular modeling and predictive analytics are expediting generic drug formulation processes, reducing development timelines by up to 40% and enabling faster market entry for biosimilar and generic pharmaceutical products.
• Enhancing Quality Control Systems: Machine learning algorithms are revolutionizing pharmaceutical manufacturing quality assurance, implementing real-time monitoring systems that ensure consistent generic drug quality and compliance with SFDA safety standards across production facilities.
• Optimizing Supply Chain Management: AI-driven demand forecasting and inventory optimization systems are streamlining generic drug distribution networks, reducing stockouts by 25% and improving medication accessibility across Saudi Arabia's healthcare facilities.
• Personalizing Treatment Recommendations: AI-assisted clinical decision support systems are helping healthcare providers select the most appropriate generic drug alternatives based on patient profiles, improving treatment outcomes and reducing adverse drug reactions.
• Supporting Regulatory Compliance: Automated AI systems are enhancing regulatory submission processes for generic drug approvals, streamlining SFDA documentation requirements and accelerating the approval timeline for new generic medications entering the Saudi market.

Grab a sample PDF of this report: https://www.imarcgroup.com/saudi-arabia-generic-drug-market/requestsample

Saudi Arabia Generic Drug Market Trends & Drivers:

Saudi Arabia's generic drug market is experiencing robust growth driven by comprehensive government initiatives under Vision 2030's healthcare transformation agenda. The National Biotechnology Strategy, launched in January 2024, positions the Kingdom to become a world-class biotech hub by 2040, with specific focus on increasing domestic pharmaceutical manufacturing from the current 30% to 40% by 2030. Major international pharmaceutical companies including Pfizer, GSK, Novartis, and Hikma Pharma are establishing state-of-the-art manufacturing facilities, with Pfizer alone investing USD 50 million in regional production capabilities. These strategic investments are supported by favorable government policies, tax incentives, and regulatory frameworks designed to encourage local generic drug production and reduce import dependency.

The expanding healthcare infrastructure and rising prevalence of chronic diseases are creating substantial demand for cost-effective generic medications across Saudi Arabia. With diabetes, cardiovascular diseases, and hypertension rates increasing significantly, generic drugs offer affordable treatment solutions that align with the Kingdom's healthcare cost containment objectives. The Saudi Food and Drug Authority (SFDA) has strengthened its regulatory framework, implementing new guidelines in 2024 that require Freedom To Operate opinions for generic drug applications, ensuring robust intellectual property protection while maintaining market access. The authority approved five new therapies in January 2025, including biologics and advanced blood products, demonstrating its commitment to expanding treatment options for patients nationwide.

The digital transformation of Saudi Arabia's healthcare system is accelerating generic drug adoption through enhanced prescription management and medication monitoring systems. Electronic medical records and digital health technologies are facilitating better prescription practices, improving medication adherence, and increasing accessibility to generic alternatives. Strategic partnerships between local and international pharmaceutical companies are expanding the availability of diverse generic medication portfolios, while growing health insurance coverage makes generic drugs more affordable for patients. The expanding retail and hospital pharmacy networks, combined with increasing public awareness of generic drug efficacy and safety, are driving sustained market growth across all therapeutic areas including central nervous system, cardiovascular, diabetes, and oncology segments.

We explore the factors driving the growth of the market, including technological advancements, consumer behaviors, and regulatory changes, along with emerging Saudi Arabia generic drug market trends.

Saudi Arabia Generic Drug Industry Segmentation:

The report has segmented the market into the following categories:

Therapy Area Insights:

• Central Nervous System
• Cardiovascular
• Dermatology
• Genitourinary/Hormonal
• Respiratory
• Rheumatology
• Diabetes
• Oncology
• Others

Drug Delivery Insights:

• Oral
• Injectables
• Dermal/Topical
• Inhalers

Distribution Channel Insights:

• Retail Pharmacies
• Hospital Pharmacies

Breakup by Region:

• Northern and Central Region
• Western Region
• Eastern Region
• Southern Region

Competitive Landscape:

The competitive landscape of the industry has also been examined along with the profiles of the key players.

Recent News and Developments in Saudi Arabia Generic Drug Market

• January 2025: Saudi Arabia launched the National Biotechnology Strategy to become a world-class biotech hub by 2040, as part of Vision 2030's broader initiative to position the country as a biotech leader in the Middle East and North Africa region, with a significant focus on generic drug manufacturing capabilities.
• October 2025: The Saudi Food and Drug Authority (SFDA) approved five new therapies, including biologics and advanced blood products, expanding treatment options for patients across the Kingdom and demonstrating the authority's commitment to enhancing pharmaceutical accessibility and innovation.
• 2025: The SFDA implemented new regulatory guidelines requiring generic companies to accompany their Marketing Authorisation applications with Freedom To Operate opinions and confirmatory undertakings, strengthening intellectual property protection while ensuring continued market access for generic pharmaceutical products.

Note: If you require specific details, data, or insights that are not currently included in the scope of this report, we are happy to accommodate your request. As part of our customization service, we will gather and provide the additional information you need, tailored to your specific requirements. Please let us know your exact needs, and we will ensure the report is updated accordingly to meet your expectations.

About Us:

IMARC Group is a global management consulting firm that helps the world's most ambitious changemakers to create a lasting impact. The company provide a comprehensive suite of market entry and expansion services. IMARC offerings include thorough market assessment, feasibility studies, company incorporation assistance, factory setup support, regulatory approvals and licensing navigation, branding, marketing and sales strategies, competitive landscape and benchmarking analyses, pricing and cost research, and procurement research.

Contact Us:

IMARC Group

134 N 4th St. Brooklyn, NY 11249, USA

Email: sales@imarcgroup.com

Tel No:(D) +91 120 433 0800

United States: +1-201971-6302